Partial Substitution of Thyroxine (T4) with Tri-Iodothyronine in Patients on T4Replacement Therapy: Results of a Large Community-Based Randomized Controlled Trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Conflicting results have recently been published about the benefits of combined T(4) and T(3) in treating hypothyroid patients. However, these studies may have been underpowered to detect differences in psychological well-being specifically related to T(4) replacement. We conducted a large, double-blind, randomized controlled trial of partial substitution of 50 microg T(4) by 10 microg T(3) vs. the original dose of T(4) in 697 hypothyroid patients. Thyroid function showed a rise in TSH (132%), a fall in free T(4) (35%, P < 0.001), and unchanged basal free T(3) levels (P = 0.92). At 3 months, there was a large (39%) placebo effect improvement in psychiatric caseness defined by the General Health Questionnaire (GHQ) 12 score in the control group compared with baseline, and this was sustained at 12 months. Differences vs. the intervention (T(3)) group were more modest with improvements in GHQ caseness (odds ratio, 0.61; 95% confidence interval, 0.42, 0.90; P = 0.01) and Hospital Anxiety and Depression questionnaire-anxiety scores at 3 months (P < 0.03) but not GHQ Likert scores, Hospital Anxiety and Depression questionnaire-depression, thyroid symptoms, or visual analog scales of mood and the initial differences were lost at 12 months. These results may be consistent with a subgroup of patients showing transient improvement after partial substitution with T(3) but do not provide conclusive evidence of specific benefit from partial substitution of T(4) by T(3) in patients on T(4)…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“superiority on a minority of measures at certain time points was seen in two trials contributing 633 participants (47,48)”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“whereas patients from another trial of 697 patients (611 with follow-up data; 573 still on study medication) had no treatment preference (47).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“Of the 14 combination therapy trials that have been completed, 10 employed once-daily LT3 administration (23,46,47,49,51,52,59,71,78,79), 4 employed twice-daily LT3 therapy (17,48,53,60), and none used three times a day LT3 therapy.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“Three trials of synthetic combination therapy (17,47,52) and one of DTE (58) have used thyroid-specific PROs.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“This was not achieved in five trials, with two trials having a lower TSH in the combination therapy group (including the Appelhof trial in 5:1 ratio group) (53,71), and three trials having a higher serum TSH in the combination therapy group (47,52,58).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779 · cited 10×
“However, no difference was seen in the TSQ scores, sleep, neuromuscular symptoms, HADS depression category, or visual analog scales, and the percentage of patients reporting that they felt better on direct questioning was not different (well-being question, Table 2).”
MethodInfluentialHollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279 · cited 6×
“808 J Clin Endocrinol Metab, February 2005, 90(2):805–812 Saravanan et al.”
BackgroundInfluentialThe Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657 · cited 5×
“The GHQ-12 and the TSQ were scored both by the Likert method (0–3 per question, maximum score 36-most dissatisfied, linear method) and by the GHQ method (0, 0, 1, 1, maximum score 12-most dissatisfied) to assess caseness (using a threshold score of 3 or more, categorical method) (23, 24).”
MethodInfluentialThe Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey
Vanderpump, M. P. J., Tunbrldge, W. M. G., French, J. M., Appleton, D., Bates, D., Clark, F., Evans, J. G., Hasan, D. M., Rodgers, H., Tunbridge, F., et al. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01894.x · Cited by 2,432
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 12×
“The GHQ-12 and the TSQ were scored both by the Likert method (0–3 per question, maximum score 36-most dissatisfied, linear method) and by the GHQ method (0, 0, 1, 1, maximum score 12-most dissatisfied) to assess caseness (using a threshold score of 3 or more, categorical method) (23, 24).”
BackgroundMethodInfluentialSelf-citationBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 1×
“5 g T3 significantly improves mood although not cognitive function (17), but more recently, five other trials have shown either no benefit (18–21) or a worse outcome (22).”
BackgroundValidation of the General Health Questionnaire in a young community sample
Banks, M. H. (1983) · Psychological Medicine · doi:10.1017/s0033291700050972 · Cited by 383
Zulewski, H., Müller, B., Exer, P., Miserez, A. R., & Staub, J.-J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3810 · Cited by 338
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“The impact of combination LT4/ LT3 treatment on serum TSH levels measured at study completion was as follows: (i) no significant difference compared to LT4 therapy alone—eight studies (384,387,388,517,518, 520,521,524); (ii) significantly higher TSH measurement in the combination therapy group compared to the LT4 grou…”
InfluentialA genome-wide association study identifies protein quantitative trait loci (pQTLs)
Melzer, D., Perry, J. R. B., Hernandez, D., Corsi, A.-M., Stevens, K., Rafferty, I., Lauretani, F., Murray, A., Gibbs, J. R., Paolisso, G., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000072 · Cited by 480
“Further details have been previously published [44].”
Self-citation2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Deiodinases and their intricate role in thyroid hormone homeostasis
Luongo, C., Dentice, M., & Salvatore, D. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0218-2 · Cited by 332
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
“The study design has been previously described (18), but briefly, subjects on a stable dose of T4 therapy 100 g or more per day were recruited from 28 primary care practices in the Weston-superMare and Bristol areas of the United Kingdom and randomized to either combination T4/T3 therapy (original dose minus 50 g of T…”
BackgroundMethodInfluentialSelf-citationGrozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296
“Escobar-Morreale 2005 (15) Yes A, computer-generated sequence of randomization A, central allocation by independent investigator No Double blind VAS; POMS; Digit Symbol Test; Digit Span Test (forward and backward); SF 36 (general health) Levitt 2005 (20) No A, randomization tables B, capsules prepared by pharmacy No D…”
BackgroundMethodThyroid-hormone therapy and thyroid cancer: a reassessment
Biondi, B., Filetti, S., & Schlumberger, M. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0020 · Cited by 224
Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
Jonklaas, J. (2008) · JAMA · doi:10.1001/jama.299.7.769 · Cited by 216
“Additional problems have included lack of placebo control(20,25,27) and improvement in symptoms in the placebo group.(21,24,28) The inability to confirm that combined LT4 and T3 therapy is beneficial could potentially be interpreted in many different ways.”
BackgroundHashimoto thyroiditis: an evidence-based guide: etiology, diagnosis and treatment
Klubo-Gwiezdzinska, J., & Wartofsky, L. (2022) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16222 · Cited by 207
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
Self-citationWalsh, J. P., Ward, L. C., Burke, V., Bhagat, C. I., Shiels, L., Henley, D., Gillett, M. J., Gilbert, R., Tanner, M., & Stuckey, B. G. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0099 · Cited by 164
Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., & de Escobar, G. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0184 · Cited by 160
“(39) used 10 g liothyronine to substitute 50 g of the usual levothyroxine dose of the patients in a parallel randomized design including 697 patients.”
MethodPanicker, V., Cluett, C., Shields, B., Murray, A., Parnell, K. S., Perry, J. R. B., Weedon, M. N., Singleton, A., Hernandez, D., Evans, J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0397 · Cited by 155
Self-citationNygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0542 · Cited by 153
Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4107 · Cited by 151
Primary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Dayan, C. M., & Panicker, V. (2013) · European Thyroid Journal · doi:10.1159/000353777 · Cited by 142
Self-citationCeli, F. S., Zemskova, M., Linderman, J. D., Smith, S., Drinkard, B., Sachdev, V., Skarulis, M. C., Kozlosky, M., Csako, G., Costello, R., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1329 · Cited by 125
Combination Treatment with T4 and T3: Toward Personalized Replacement Therapy in Hypothyroidism?
Biondi, B., & Wartofsky, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3399 · Cited by 124
Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism
Wiersinga, W. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.258 · Cited by 114
Wyne, K. L., Nair, L., Schneiderman, C. P., Pinsky, B., Antunez Flores, O., Guo, D., Barger, B., & Tessnow, A. H. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac172 · Cited by 111
“Some patients may also be prescribed liothyronine, a synthetic triiodothyronine (T3) replacement therapy, despite clinical trials demonstrating little to no effect on symptoms of HT [6-8].”
BackgroundClinical aspects of thyroid function during ageing
Chaker, L., Cappola, A. R., Mooijaart, S. P., & Peeters, R. P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30028-7 · Cited by 94
Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism
Chao, M., Jiawei, X., Xia, H., Guoming, W., Yangang, W., Xufu, W., & Shuyao, Z. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832c79e0 · Cited by 93
Saravanan, P., Visser, T. J., & Dayan, C. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0414 · Cited by 90
“Entry criteria for the WATTS have previously been published (12) and included age between 18 and 75 yr and T4 replacement at a dose of 100 g/d or more, unchanged for a minimum of 3 months and with a TSH level reported to be in the laboratory reference range in the preceding 15 months.”
BackgroundMethodInfluentialSelf-citationOptimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Samuels, M. H., Kolobova, I., Smeraglio, A., Peters, D., Purnell, J. Q., & Schuff, K. G. (2016) · Thyroid · doi:10.1089/thy.2015.0345 · Cited by 87
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationFadeyev, V. V., Morgunova, T. B., Melnichenko, G. A., & Dedov, I. I. (2010) · Hormones · doi:10.14310/horm.2002.1274 · Cited by 77
Printing T3 and T4 oral drug combinations as a novel strategy for hypothyroidism
Alomari, M., Vuddanda, P. R., Trenfield, S. J., Dodoo, C. C., Velaga, S., Basit, A. W., & Gaisford, S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.062 · Cited by 77
Liothyronine use in a 17 year observational population‐based study ‐ the tears study
Leese, G. P., Soto‐Pedre, E., & Donnelly, L. A. (2016) · Clinical Endocrinology · doi:10.1111/cen.13052 · Cited by 75
Thyroxine replacement: a clinical endocrinologist’s viewpoint
Eligar, V, Taylor, P., Okosieme, O., Leese, G., & Dayan, C. (2016) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216642255 · Cited by 72
“Parallel 71 No Yes – – – – Saravanan et al.(105) Parallel 697 No No No – – – Walsh et al.”
Self-citationSantoro, N. F., Braunstein, G. D., Butts, C. L., Martin, K. A., McDermott, M., & Pinkerton, J. V. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1271 · Cited by 83
Valizadeh, M., Seyyed-Majidi, M. R., Hajibeigloo, H., Momtazi, S., Musavinasab, N., & Hayatbakhsh, M. R. (2009) · Endocrine Research · doi:10.1080/07435800903156340 · Cited by 65
“The findings of our study that combination of LT4 and LT3 provides no significant on patients’ psychosocial outcomes relative to only LT4 therapy support the results previously found by either crossover (18,19,23) or paralleldesign (17,21,22) randomized trials.”
ResultCeli, F. S., Zemskova, M., Linderman, J. D., Babar, N. I., Skarulis, M. C., Csako, G., Wesley, R., Costello, R., Penzak, S. R., & Pucino, F. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03700.x · Cited by 65
Perros, P., Van Der Feltz‐Cornelis, C., Papini, E., Nagy, E. V., Weetman, A. P., & Hegedüs, L. (2023) · Clinical Endocrinology · doi:10.1111/cen.14473 · Cited by 65
Dayan, C., & Panicker, V. (2018) · Thyroid Research · doi:10.1186/s13044-018-0045-x · Cited by 62
“als of thyroid hormone replacement [26] and the fact that LT3 may initially give a feeling of euphoria, clini-”
BackgroundSelf-citationMillan-Alanis, J. M., González-González, J. G., Flores-Rodríguez, A., Singh Ospina, N., Maraka, S., Moreno-Peña, P. J., Brito, J. P., González-Velázquez, C., & Rodríguez-Gutiérrez, R. (2021) · Thyroid® · doi:10.1089/thy.2021.0270 · Cited by 60
Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism
Idrees, T., Palmer, S., Maciel, R. M. B., & Bianco, A. C. (2020) · Thyroid® · doi:10.1089/thy.2020.0153 · Cited by 58
Joffe, R. T., Brimacombe, M., Levitt, A. J., & Stagnaro-Green, A. (2007) · Psychosomatics · doi:10.1176/appi.psy.48.5.379 · Cited by 57
The use of triiodothyronine (T3) in the treatment of bipolar depression: A review of the literature
Parmentier, T., & Sienaert, P. A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.071 · Cited by 52
Hennessey, J. V., & Espaillat, R. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13062 · Cited by 49
Do we need still more trials on T4 and T3 combination therapy in hypothyroidism?
Wiersinga, W. M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0879 · Cited by 45
The Genetic Basis of Thyroid Function: Novel Findings and New Approaches
Kuś, A., Chaker, L., Teumer, A., Peeters, R. P., & Medici, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz225 · Cited by 44
“In 2009, Panicker et al (93) performed a retrospective analysis in 552 hypothyroid patients from the Weston Area T4 /T3 Study (WATTS), in which patients on a stable dose of LT4 therapy were previously randomized to either LT4/LT3 combination therapy or the original LT4 monotherapy dose (94).”
MethodTariq, A., Wert, Y., Cheriyath, P., & Joshi, R. (2018) · Southern Medical Journal · doi:10.14423/smj.0000000000000823 · Cited by 43
“Similarly, a study of 697 patients found slight improvements in hypothyroid symptoms during 3 months of synthetic therapy, but these results were nonreplicable 1 year later.(15) Escobar-Morreale and colleagues reported that synthetic therapy appeared to have no beneficial effects on mood, quality of life, and psychome…”
ResultRazvi, S., McMillan, C. V., & Weaver, J. U. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02381.x · Cited by 43
Combination L-T3 and L-T4 therapy for hypothyroidism
Wartofsky, L. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/01.med.0000432611.03732.49 · Cited by 42
Emerging role of thyroid hormone metabolites
Gnocchi, D., Steffensen, K. R., Bruscalupi, G., & Parini, P. (2016) · Acta Physiologica · doi:10.1111/apha.12648 · Cited by 50
“In fact, T4 replacement therapy restored normal circulating TSH levels, although in some patients this does not result in a recovery of euthyroidism in several tissues, resulting in the socalled subclinical hypothyroidism (Saravanan et al. 2005).”
BackgroundKaminski, J., Miasaki, F. Y., Paz-Filho, G., Graf, H., & Carvalho, G. A. D. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000192 · Cited by 42
“Furthermore, no significant changes were detected in arterial blood pressure, in concordance with previous clinical trials (10-12,22-24,32).”
BackgroundMethodResultInfluentialTaylor, P. N., Panicker, V., Sayers, A., Shields, B., Iqbal, A., Bremner, A. P., Beilby, J. P., Leedman, P. J., Hattersley, A. T., Vaidya, B., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0938 · Cited by 41
Self-citationPhysician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics
Jonklaas, J., Tefera, E., & Shara, N. (2018) · Thyroid · doi:10.1089/thy.2018.0325 · Cited by 41
Do Patients Gain Weight After Thyroidectomy for Thyroid Cancer?
Weinreb, J. T., Yang, Y., & Braunstein, G. D. (2011) · Thyroid · doi:10.1089/thy.2010.0393 · Cited by 40
“However, it appears that this parameter, as has been shown by others, appears unchanged with levothyrox-ine treatment alone, at least in short-term studies (11–14).”
de Carvalho, G. A., Paz-Filho, G., Mesa Junior, C., & Graf, H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0947 · Cited by 40
Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level
Jonklaas, J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000355 · Cited by 38
Akirov, A., Fazelzad, R., Ezzat, S., Thabane, L., & Sawka, A. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00477 · Cited by 37
Liothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality
Planck, T., Hedberg, F., Calissendorff, J., & Nilsson, A. (2021) · Thyroid® · doi:10.1089/thy.2020.0388 · Cited by 35
Ahluwalia, R., Baldeweg, S. E., Boelaert, K., Chatterjee, K., Dayan, C., Okosieme, O., Priestley, J., Taylor, P., Vaidya, B., Zammitt, N., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14935 · Cited by 34
Self-citationThyroid hormone replacement: current status and challenges
Okosieme, O. E. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.600307 · Cited by 35
“Briefly, some protocols used fixed T3 doses in combination with varying amounts of T4 resulting in a range of T3:T4 ratios that do not mimic the human thyroid secretion ratio of 1:14 (Table 2) [83-85,88-90,93-95].”
BackgroundMethodInfluentialThyroid Hormone Replacement Therapy: Three Simple Questions, Complex Answers
Bianco, A. C., & Casula, S. (2012) · European Thyroid Journal · doi:10.1159/000339447 · Cited by 32
Regalbuto, C., Maiorana, R., Alagona, C., Paola, R. D., Cianci, M., Alagona, G., Sapienza, S., Squatrito, S., & Pezzino, V. (2007) · Thyroid · doi:10.1089/thy.2006.0084 · Cited by 32
“These studies were not confirmed by a variety of subsequent observations, all indicating no additional benefit from the combined LT4 = LT3 therapy (9–17).”
Prescribing Therapy for Hypothyroidism: Influence of Physician Characteristics
Jonklaas, J., Tefera, E., & Shara, N. (2019) · Thyroid · doi:10.1089/thy.2018.0369 · Cited by 31
Hypothyroidism: Cardiovascular Endpoints of Thyroid Hormone Replacement
Stamatouli, A. M., Bedoya, P., & Yavuz, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00888 · Cited by 40
Kraut, E., & Farahani, P. (2015) · Clinical and Investigative Medicine · doi:10.25011/cim.v38i6.26194 · Cited by 30
Escobar-Morreale, H. F., Botella-Carretero, J. I., & Morreale de Escobar, G. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.10.004 · Cited by 30
DiStefano, J., & Jonklaas, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00746 · Cited by 28
Risks and safety of combination therapy for hypothyroidism
Jonklaas, J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1182019 · Cited by 27
The Challenges and Complexities of Thyroid Hormone Replacement
Kansagra, S. M., McCudden, C. R., & Willis, M. S. (2010) · Laboratory Medicine · doi:10.1309/lmb39th2fzgndgim · Cited by 34
Jonklaas, J., Tefera, E., & Shara, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00031 · Cited by 23
Brigante, G., Santi, D., Boselli, G., Margiotta, G., Corleto, R., Monzani, M. L., Craparo, A., Locaso, M., Sperduti, S., Roy, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad172 · Cited by 23
Liothyronine cost and prescriptions in England
Taylor, P. N., Razvi, S., Muller, I., Wass, J., Dayan, C. M., Chatterjee, K., & Boelaert, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30334-6 · Cited by 19
Self-citationSesmilo, G., Simó, O., Choque, L., Casamitjana, R., Puig-Domingo, M., & Halperin, I. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.09.006 · Cited by 18
For Some, l-Thyroxine Replacement Might Not Be Enough: A Genetic Rationale
Kim, B. W., & Bianco, A. C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0410 · Cited by 18
Optimal Hormone Replacement Therapy in Hypothyroidism - A Model Predictive Control Approach
Wolff, T. M., Dietrich, J. W., & Müller, M. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884018 · Cited by 27
Krysiak, R., Szkróbka, W., & Okopień, B. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1448771 · Cited by 17
Combination Therapy for Hypothyroidism: Rationale, Therapeutic Goals, and Design
Madan, R., & Celi, F. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00371 · Cited by 18
Does Combination T4 And T3 Therapy Make Sense?
McDermott, M. T. (2012) · Endocrine Practice · doi:10.4158/ep12076.ra · Cited by 17
Cho, Y. Y., Kim, H. J., Jang, H. W., Kim, T. H., Ki, C., Kim, S. W., & Chung, J. H. (2017) · Endocrine · doi:10.1007/s12020-017-1307-4 · Cited by 17
Mazzaferri, E. L. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70611-4 · Cited by 12
Bahl, S., Taylor, P. N., Premawardhana, L. D., Stedman, M., Heald, A., Dayan, C. M., & Okosieme, O. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf449 · Cited by 11
Self-citationPetnehazy, E., & Buchinger, W. (2019) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-019-0691-1 · Cited by 12
Latrofa, F., & Pinchera, A. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-517-6_7 · Cited by 15
Hypothyreose – wann und wie behandeln?
Koehler, V. F., Reincke, M., & Spitzweg, C. (2018) · Der Internist · doi:10.1007/s00108-018-0438-x · Cited by 14
Mazzaferri, E. L. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70362-7 · Cited by 10
Triiodothyronine alongside levothyroxine in the management of hypothyroidism?
Gottwald-Hostalek, U., & Kahaly, G. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1984219 · Cited by 9
Vargas‐Uricoechea, H., & Wartofsky, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179218 · Cited by 15
Phan, G. Q., Yavuz, S., Stamatouli, A. M., Madan, R., Chen, S., Grover, A. C., Nilubol, N., Bedoya, P., Trankle, C. R., Markley, R., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1522753 · Cited by 9
Bjerkreim, B. A., Hammerstad, S. S., Gulseth, H. L., Berg, T. J., Lee-Ødegård, S., & Eriksen, E. F. (2022) · Journal of Thyroid Research · doi:10.1155/2022/6423023 · Cited by 8
Role of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism
Jonklaas, J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.003 · Cited by 10
Hughes, D. A., Skiadas, K., Fitzsimmons, D. F., Anderson, P., & Heald, A. H. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051702 · Cited by 7
Pappy, A. L., Oyesiku, N. M., & Ioachimescu, A. G. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616661834 · Cited by 8
Combined therapy with levothyroxine and liothyronine for hypothyroidism
Fischman, A., & Domínguez, J. M. (2018) · Medwave · doi:10.5867/medwave.2018.08.7375 · Cited by 7
Gottwald-Hostalek, U., & Tayrouz, Y. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2435460 · Cited by 6
Jonklaas, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-72102-6_19 · Cited by 6
Alternative and Complementary Treatment of Thyroid Disorders
Onumah, B. M. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3314-3_69 · Cited by 6
Prevalence and severity of fatigue in treated hypothyroidism: results of a UK survey
Grixti, L., Fisher, H., Priestley, J., McMullan, C., Woollven, A., Perros, P., Mitchell, A. L., Gan, E. H., & Pearce, S. H. S. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0044 · Cited by 5
Gluvic, Z. M., Sudar-Milovanovic, E. M., Samardzic, V. S., Obradovic, M. M., Jevremović, D., Radenković, S., & Isenović, E. R. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109299 · Cited by 6
Pepper, G. M., & Casanova-Romero, P. Y. (2014) · Cited by 7
Guglielmi, R., Mian, C., Novizio, R., Paoletta, A., Persichetti, A., Samperi, I., Scoppola, A., Bagnasco, M., Menis, E. D., Rimini, M. L. D., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02652-y · Cited by 6
Fussey, J. M., Khan, H., Ahsan, S. F., Prashant, R., & Pettit, L. (2017) · Head & Neck · doi:10.1002/hed.24926 · Cited by 5
Heald, A. H., Livingston, M. A., & Hughes, D. A. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1062-6167 · Cited by 5
Chen, S., Wohlford, G. F., Vecchié, A., Carbone, S., Yavuz, S., Tassell, B. W. V., Abbate, A., & Celi, F. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.843539 · Cited by 4
Metadata
- Authors
- Saravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J., & Dayan, C. M.
- Affiliations
- University of Bristol (GB)
- Bristol Royal Infirmary (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-02
- Volume
- 90
- Issue
- 2
- Pages
- 805-812
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2054867435
- Cited by
- 136
- References
- 25
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 3 · 2022: 8 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 14 · 2017: 3 · 2016: 11 · 2015: 5 · 2014: 5 · 2013: 3 · 2012: 7
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- hypothyroidism, thyroxine replacement, triiodothyronine, placebo effect, psychiatric symptoms, anxiety, depression, thyroid function, thyroid-stimulating hormone, free thyroxine
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Follow-Up Studies, Humans, Hypothyroidism, Middle Aged, Thyrotropin, Thyroxine, Time Factors, Triiodothyronine, Reproducibility of Results, Treatment Outcome, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.